Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05066178 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Speech Treatment for Minimally Verbal Children With ASD and CAS

Study acronym: TxMVASD+CAS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Apr 30, 2026 to Apr 30, 2030
    • Study completion date: Nov 30, 2026 to Nov 30, 2030
    v7
  2. Primary completion date: Nov 30, 2024 to Apr 30, 2026
    • Study completion date: Nov 30, 2024 to Nov 30, 2026
    v6
  3. Start date: Jan 1, 2024 to May 1, 2024v5
  4. Eligibility criteria shortened, about 15 wordsv4
  5. Study completion date: Nov 30, 2025 to Nov 30, 2024v3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Nov 30, 2023 to Nov 30, 2024
    • Start date: Jan 1, 2022 to Jan 1, 2024
    • Study sites: 0 to 1
    • Study completion date: Nov 30, 2024 to Nov 30, 2025
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.
Trial Details
NCT Number NCT05066178
Lead Sponsor MGH Institute of Health Professions
Conditions
(from sponsor)		 Developmental Verbal Dyspraxia, Autism Spectrum Disorder
Related terms Apraxias, Autism Spectrum Disorder, Autistic Disorder
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov